ELOX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Eloxx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$1.39 |
| 52 Week Low | US$0.000001 |
| Beta | -24.83 |
| 1 Month Change | -99.00% |
| 3 Month Change | -99.00% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Eloxx says lead asset failed in mid-stage cystic fibrosis trial
Sep 14Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line
Aug 15Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?
Sep 09
Eloxx Pharmaceuticals EPS misses by $0.06
May 06What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?
Feb 17Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis
Jan 13Shareholder Returns
| ELOX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -2.6% |
| 1Y | -100.0% | 3.2% | 24.5% |
Return vs Industry: ELOX underperformed the US Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: ELOX underperformed the US Market which returned 23.1% over the past year.
Price Volatility
| ELOX volatility | |
|---|---|
| ELOX Average Weekly Movement | 6,511.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ELOX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ELOX's weekly volatility has decreased from 10443% to 6511% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Sumit Aggarwal | www.eloxxpharma.com |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology.
Eloxx Pharmaceuticals, Inc. Fundamentals Summary
| ELOX fundamental statistics | |
|---|---|
| Market cap | US$3.00 |
| Earnings (TTM) | -US$20.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ELOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELOX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.48m |
| Earnings | -US$20.48m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -91.8% |
How did ELOX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 13:13 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eloxx Pharmaceuticals, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |
| Andrew Fein | H.C. Wainwright & Co. |